Sam Chun Dang Pharm Co Ltd banner
S

Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250

Watchlist Manager
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Watchlist
Price: 825 000 KRW 8.98% Market Closed
Market Cap: ₩19.4T

Gross Margin

47%
Current
Declining
by 1.8%
vs 3-y average of 48.8%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
47%
=
Gross Profit
₩103.7B
/
Revenue
₩220.7B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
47%
=
Gross Profit
₩103.7B
/
Revenue
₩220.7B

Peer Comparison

Country Company Market Cap Gross
Margin
KR
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
19.2T KRW
Loading...
US
Eli Lilly and Co
NYSE:LLY
987.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
596.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
293B CHF
Loading...
CH
Novartis AG
SIX:NOVN
249.7B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
240.5B GBP
Loading...
US
Merck & Co Inc
NYSE:MRK
307.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
156.9B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD
Loading...

Market Distribution

Higher than 83% of companies in Korea
Percentile
83nd
Based on 2 511 companies
83nd percentile
47%
Low
-646.5% — 12.8%
Typical Range
12.8% — 32.2%
High
32.2% — 54 001.3%
Distribution Statistics
Korea
Min -646.5%
30th Percentile 12.8%
Median 19.7%
70th Percentile 32.2%
Max 54 001.3%

Sam Chun Dang Pharm Co Ltd
Glance View

Market Cap
19.4T KRW
Industry
Pharmaceuticals

Sam Chun Dang Pharm Co Ltd is a quintessential tale of innovation and resilience in the ever-evolving pharmaceutical landscape. Founded in 1943, this South Korean company has steadily crafted its way into becoming a significant player in the generic drug market. Initially focusing on traditional herbal remedies, the company astutely shifted its focus towards the production of generic drugs, capitalizing on the increasing demand for cost-effective alternatives to branded medications. Sam Chun Dang's business model pivots on manufacturing and distributing a wide range of pharmaceutical products, including prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients, catering to both domestic and international markets. The company thrives by meticulously investing in research and development, ensuring a robust pipeline of new generics ready for market entry as patents on branded drugs expire. By emphasizing quality and affordability, Sam Chun Dang Pharm Co Ltd leverages its state-of-the-art manufacturing facilities, accredited by international standards, to maintain a competitive edge. Their profitability stems from not only their comprehensive product lineup but also strategic partnerships and collaborations that enhance their market penetration. Despite operating within a highly competitive and regulated industry, Sam Chun Dang’s commitment to consistent quality and innovation helps them sustain revenue growth and solidify their position as a reputable pharmaceutical provider.

Intrinsic Value
7 990.92 KRW
Overvaluation 99%
Intrinsic Value
Price
S
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
47%
=
Gross Profit
₩103.7B
/
Revenue
₩220.7B
What is Sam Chun Dang Pharm Co Ltd's current Gross Margin?

The current Gross Margin for Sam Chun Dang Pharm Co Ltd is 47%, which is below its 3-year median of 48.8%.

How has Gross Margin changed over time?

Over the last 3 years, Sam Chun Dang Pharm Co Ltd’s Gross Margin has decreased from 49.3% to 47%. During this period, it reached a low of 46.8% on Jun 30, 2025 and a high of 51.4% on Jun 30, 2023.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett